Chief Financial Officer · UroGen Pharma Ltd. (URGN)

Chris Degnan

FY2024 is the first fiscal year CompBrief holds for Chris Degnan as a named executive officer of UroGen Pharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,053,789

Salary $115,530Stock awards $176,330

4th of 4 named executive officers at UroGen Pharma by FY2024 total.

4 named officers on file for UroGen Pharma, FY2024

Chris Degnan’s pay file — $29

  • 1 fiscal year of pay, line by line
  • URGN’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how UroGen Pharma’s whole pay program stands against its peers

  • UroGen Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on URGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 15, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Chris Degnan’s full pay file as a PDF — free

More than this page: up to 10 years of Chris’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Chris Degnan compensation by year

UroGen Pharma Summary Compensation Table · the one fiscal year held
In US dollars, as UroGen Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$115,530
Bonus$0
Stock awards$176,330
Option awards$695,294
Non-equity incentive$53,125
Pension and deferred compensation$0
All other$13,510
Total$1,053,789

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: UroGen Pharma Ltd. DEF 14A filed July 15, 2025, accession 0001437749-25-022732, and prior-year filings. Open the filing on EDGAR.

How this page was built: the UroGen Pharma Ltd. filed document, accession 0001437749-25-022732. Every figure is read from that document and cited to the page and table it appears in. Filed July 15, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU13,450$143,243—
Option74,142—$13.11

Per the Outstanding Equity Awards at Fiscal Year-End table in UroGen Pharma Ltd.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

7 Form 4 lines since the FY2024 proxy (filed July 15, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-10-08Exercise or conversion—4,483—6,763
2026-10-08Sale—2,202$36.694,561
2026-10-08Exercise or conversion derivative—4,483$0.004,484
2026-01-31Grant or award derivative—32,609$0.0032,609
2025-10-08Sale—2,203$16.852,280
2025-10-08Exercise or conversion—4,483—4,483
2025-10-08Exercise or conversion derivative—4,483$0.008,967

The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

UroGen Pharma’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Elizabeth BarrettChief Executive Officer$4,149,858
Don KimFormer Chief Financial Officer$1,364,222
Jason SmithGeneral Counsel and Chief Compliance Officer$1,275,464
Chris Degnan · this pageChief Financial Officer$1,053,789

The full UroGen Pharma compensation record

free company brief

This page is one person within UroGen Pharma's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the UroGen Pharma proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are UroGen Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Chris Degnan's compensation dossier · One-time report. No refunds.